Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, China.
Department of Pharmacy, Center for Precision Cancer Medicine, Clinical Oncology Pharmacist Training Bases (National Health Commission), Qingdao Municipal Hospital, Qingdao University, Qingdao, China.
Genet Test Mol Biomarkers. 2021 Mar;25(3):236-246. doi: 10.1089/gtmb.2020.0131.
To assess the expression and epigenetic regulation of Syncoilin, intermediate filament protein () in gastric cancer tissues, and to determine its associations with clinicopathological features; immune infiltration of macrophages in tumors; and patient survival. Clinicopathological features, expression profiles, and methylation data of the gene were obtained from multi-institutional real-world public datasets. A total of 1601 samples from patients with gastric cancer were examined. The associations between clinicopathological features and expression levels were assessed by the chi-square test; survival was assessed using the Kaplan-Meier analysis. The infiltration levels of M1, 2-polarized tumor-associated macrophages (TAMs) in a gastric tumor immune microenvironment were quantified using deconvolution, and the correlation between expression level and M1, 2-polarized macrophages' infiltration was examined using the Pearson correlation test. gene methylation data were analyzed to investigate epigenetic control of its expression. expression was elevated in gastric cancer tissues ( < 0.01), and was associated with a poorer overall survival ( < 0.01) and poorer postprogression survival ( = 0.01). Higher levels were significantly associated with more aggressive clinicopathological features in gastric cancer patients ( < 0.05). was also associated with the infiltration of M2-polarized TAMs in the gastric tumor immune microenvironment ( < 0.001). Hypomethylation was shown to be associated with s upregulation ( < 0.05). is highly expressed in gastric cancer tissues and has the potential to be a therapeutic target and to serve as a prognostic marker.
为了评估突触联丝蛋白(Syncoilin)在胃癌组织中的表达和表观遗传调控,并确定其与临床病理特征的关系;肿瘤中巨噬细胞的免疫浸润;以及患者的生存情况。从多机构真实世界公共数据集获得了临床病理特征、基因表达谱和甲基化数据。共检测了 1601 例胃癌患者的样本。采用卡方检验评估临床病理特征与基因表达水平的关系;采用 Kaplan-Meier 分析评估生存情况。使用去卷积量化胃肿瘤免疫微环境中 M1、2 极化肿瘤相关巨噬细胞(TAMs)的浸润水平,并使用 Pearson 相关检验检验基因表达水平与 M1、2 极化巨噬细胞浸润的相关性。分析基因甲基化数据,研究其表达的表观遗传调控。Syncoilin 基因在胃癌组织中表达上调(<0.01),与总生存期(<0.01)和后进展生存期(=0.01)较差相关。较高的基因表达水平与胃癌患者更具侵袭性的临床病理特征显著相关(<0.05)。Syncoilin 还与胃肿瘤免疫微环境中 M2 极化 TAMs 的浸润相关(<0.001)。低甲基化与基因上调相关(<0.05)。Syncoilin 在胃癌组织中高表达,具有作为治疗靶点和预后标志物的潜力。